Answers are grounded in this paper and cite their sources.
Cross-sectional study reveals elevated serum Bcl-2 in bipolar mania patients, suggesting neuroinflammatory involvement.
Introduction: The B-cell lymphoma-2 (Bcl-2) protein plays an essential role in the regulation of cell survival. Bcl-2 has neuroprotective and anti-apoptotic functions that have been linked to the neuroinflammatory hypothesis of bipolar disorder (BD). Mood stabilizer treatment for BD has been found to upregulate the Bcl-2 gene, suggesting a mechanism for their therapeutic effects. Certain single-nucleotide polymorphisms in Bcl-2 mRNA have also been linked to BD, highlighting the importance of Bcl-2 abnormalities in BD neurobiology. Aim: The aim of the current study was to determine if serum Bcl-2 levels could be used as a biomarker for BD. Methodology: In this cross-sectional study, serum Bcl-2 was measured in patients with bipolar mania, unaffected first-degree relatives (FDR), and healthy controls (HCs) (21 in each group). Furthermore, a correlation between serum Bcl-2 levels and Young Mania Rating Scale (YMRS) scores was performed to assess potential associations with manic symptoms. Results: Serum Bcl-2 concentrations were elevated in individuals with BD and their FDR when compared with HCs; however, these differences did not reach statistical significance. Additionally, serum Bcl-2 levels did not show significant correlations with age, number of mood episodes, or YMRS scores. Conclusion: Although the difference in serum Bcl-2 levels was not statistically significant among the groups, higher serum Bcl-2 levels were observed in patients and their unaffected FDRs compared to HCs. Further research using a longitudinal approach that considers the various phases of mania is needed to explore this possibility more comprehensively.
No takes yet. Share an insight, caveat, or question.
Mudaliyar et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: